Abstract
RNA isolation and qRT-PCR
For tissue samples, a precooled mortar and pestle was used to grind the frozen tissue under liquid nitrogen. TRIzol reagent (Invitrogen, Carlsbad, CA) was added to dissolve tissues and cells as soon as possible to prepare total RNA. the RNA concentration and quality. For qRT-PCR assays, cDNA was synthesized from 1 g of total RNA using a Reverse Transcription Kit (Takara, Dalian, China). The quantitative polymerase chain reaction (qPCR) assays were performed using an ABI 7500 system. GAPDH was used as a control. Primers used for target 2.
Cell transfection
Lipofectamine 2000 (Invitrogen, USA) was used to transfect siRNA into cells. Plasmid vectors (sh-SH3PXD2A-AS1 and empty vector) for transfection were extracted by DNA Midiprep kit (Qiagen, Hilden, Germany) and transfected into cells using Fugene (Roche, USA). The sequences of the siRNAs and shRNAs are described in Table  2 . Cells were harvested after 48 h for qRT-PCR and Western blot analyses. The P57 and KLF2 sequence were respectively synthesized and subcloned into the pcDNA3.1 vector (GENECHEM, Shanghai, China) to generate the pcDNA-P57 vector and pcDNA-KLF2 vector for ectopic expression in cells. pcDNA3.1 vector was used as a control. software; Bio-Rad, Hercules, CA, USA). A GAPDH (#2118, CST, USA) antibody was used as a control. The anti-CDK2 (#2546, CST, USA), anti-CDK4 (#12790, CST, USA), anti-CDK6 (#13331,CST,USA), and anti-Cyclin D1 (#2978, CST, USA) (all 1:1000) antibodies were purchased from Cell Signaling Technology, Inc. (CST). The anti-P57 (SAB5500158, Sigma) and anti-KLF2 (SAB1101046, Sigma) antibodies were purchased from Sigma.
Subcellular fractionation location
The separation of nuclear and cytosolic fractions was performed using the PARIS Kit (Life Technologies) according to the manufacturer's instructions.
RNA immunoprecipitation (RIP)
RNA immunoprecipitation was used to investigate whether SH3PXD2A-AS1 could bind with the potential binding protein (EZH2 and SUZ12). We used the EZMagna RIP kit (Millipore, Billerica, MA, USA) following the manufacturer's protocol. Cells were lysed in complete RIP lysis buffer, and the extract was (millipore) for 6 h at 4°C. Then, the beads were washed and incubated with Proteinase K to remove proteins.
Chromatin immunoprecipitation (ChIP)
Cells were treated with formaldehyde and incubated for 10 mins to generate DNA-protein cross-links. Cell lysates were then sonicated to generate chromatin fragments of 200-300 bp and Precipitated Table 2. qRT-PCR primers and sequences of siRNAs and shRNAsRT-PCR primers  Gene  Forward  Reverse  SH3PXD2A-AS1  GCCTCTTTACAGCGTTCCCT  CCTGAGGATACGTTCGTGGG  GAPDH  GAAGAGAGAGACCCTCACGCTG  ACTGTGAGGAGGGGAGATTCAGT  P15  ACGGAGTCAACCGTTTCGGGAG  GGTCGGGTGAGAGTGGCAGG  P16  ATGGAGCCTTCGGCTGACT  GGCCTCCGACCGTAACTATT  P21  CAGCAGAGGAAGACCATGTG  GGCGTTTGGAGTGGTAGAAA  P27  TGCAACCGACGATTCTTCTACTCAA  CAAGCAGTGATGTATCTGATAAACAAGG  P57  CACGATGGAGCGTCTTGTC  CCTGCTGGAAGTCGTAATCC  KLF2  TTCGGTCTCTTCGACGACG  TGCGAACTCTTGGTGTAGGTC  PTEN  AGTTCCCTCAGCCGTTACCT  AGGTTTCCTCTGGTCCTGGT  EZH2  TGCACATCCTGACTTCTGTG  AAGGGCATTCACCAACTCC  U6  CTCGCTTCGGCAGCACA  AACGCTTCACGAATTTGCGT  si-RNAs  SH3PXD2A-AS1 1#  CCACCAUUGAUAAUGAUCUUCUGAA  UUCAGAAGAUCAUUAUCAAUGGUGG  SH3PXD2A-AS1 2#  CACACAAAUCACCUGUGCAUGUUAA  UUAACAUGCACAGGUGAUUUGUGUG  SH3PXD2A-AS1 3#  GAUGGAGCUUCAGAAUUAAACUGAU In-vivo tumor model DLD-1 cells were transfected with sh-SH3PXD2A-AS1 or empty vector and harvested from six-well plates, washed with phosphate-buffered saline (PBS), and resuspended at 2 × 10 7 L of suspended cells. Tumor growth was examined every 4 days, and tumor volumes were calculated using the quation V = 0.5 × D × d² (V, volume; D, longitudinal diameter; d, latitudinal diameter). 
Results

SH3PXD2A-AS1 expression was increased in CRC tissues and correlated with tumor size, TNM stage, and lymph node metastasis in patients with CRC
To identify novel oncogenic lncRNAs involved in CRC progression, publicly available lncRNAs ( Fig. 1A-1B ). We focused on overexpressed lncRNAs showing fold changes of more than 2 in both GSE4183 and TCGA datasets, and two novel lncRNAs, SH3PXD2A-AS1 and CRNDE, were identified (Fig. 1C) . Because several research groups are already studying the role of CRNDE in carcinogenesis, including CRC progression, in this study, we decided to focus on SH3PXD2A-AS1, which was obviously upregulated in both GSE4183 and TCGA datasets (Fig.  1D) . First, qRT-PCR assays were performed to validate SH3PXD2A-AS1 expression in 68 CRC tissues and corresponding non-tumor samples, and showed that SH3PXD2A-AS1 was sigtissues compared with ad- Based on the expression levels of SH3PXD2A-AS1 in CRC, we divided 68 CRC into high (n=34, > median value) and low (n=34, < median value) SH3PXD2A-AS1 expression groups to better study the relationships between SH3PXD2A-AS1 expression and clinicopathological features of CRC patients s showed that SH3PXD2A-AS1 was obviously associated with tumor size (p=0.001), TNM stage (p=0.003), and lymph node metastasis (p=0.003) in patients with CRC -tors, such as age, gender, and location (Table 1) .
Regulation of SH3PXD2A-AS1 expression in CRC cell lines
To detect the functional effects of SH3PXD2A-AS1 in CRC cells, we examined the expression levels of SH3PXD2A-AS1 in SW480, DLD-1, HT29, LOVO and HCoEpiC cells using qRT-PCR assays (Fig. 2C ) and then altered SH3PXD2A-AS1 expression in CRC cell lines. The results showed that SH3PXD2A-AS1 expression was obviously decreased in SW480 and DLD-1 cells transfected with SH3PXD2A-AS1 siRNAs, and si-SH3PXD2A-AS1 2# and si-SH3PXD2A-AS1 3# showed higher RNA interference capacities (Fig. 2D) . Furthermore, SH3PXD2A-AS1 AS1 as compared with control cells (Fig. 9A) . Thus, si-SH3PXD2A-AS1 2#, si-SH3PXD2A-AS1 3#, empty vector, and pcDNA-SH3PXD2A-AS1 were used in subsequent studies.
Effects of SH3PXD2A-AS1 on CRC cell proliferation
Next, we performed loss-of-function and gain-of-function assays in CRC cells. MTT assays showed that SH3PXD2A-AS1 knockdown decreased cell viability in SW480 and DLD-1 colony formation and EdU assays also revealed that decreased SH3PXD2A-AS1 expression inhibited the proliferative capacities of SW480 and DLD-1 cells (Fig. 3B, 3C ). Moreover, SH3PXD2A-AS1 overexpression exhibited opposite effects (Fig. 9B, 9C ).
SH3PXD2A-AS1 regulated cell cycle progression, migration, and invasion and suppressed apoptosis in CRC
Next, we investigated the functional role of SH3PXD2A-AS1 in the regulation of cell cycle and apoptosis. Flow cytometry assays were conducted to investigate the alterations of cell cycle and apoptosis in SW480 and DLD-1 cells with SH3PXD2A-AS1 knockdown, compared with respective controls. The results showed that SW480 and DLD-1 cells transfected with SH3PXD2A-AS1 2# or 3# exhibited obvious increase in G1/G0 phase and marked decrease in G2/S phase (Fig. 4A) . Furthermore, in SW480 and DLD-1 cells transfected with SH3PXD2A-AS1 2# or 3# (Fig. 4B) . We then examined the protein level of cell-cycle-related modulators, and found remarkable alteration of cyclin D1, cyclin-dependent kinase (CDK) 2, and CDK 4 in CRC cells with SH3PXD2A-AS1 knockdown as compared with control cells (Fig. 4C ).
As our findings showed that SH3PXD2A-AS1 knockdown promoted G1/G0 phase arrest, and activated apoptosis in CRC cells, we studied whether SH3PXD2A-AS1 exerted critical roles in CRC migration and invasion through Transwell assays. The data demonstrated that SH3PXD2A-AS1 downregulation significantly inhibited cell migration and invasion (Fig.  10A) . SH3PXD2A-AS1 in nucleus was obviously higher than the portion of SH3PXD2A-AS1 in cytoplasm. U6 was used as a nucleus marker, and GAPDH was used as a cytosol marker. E. SH3PXD2A-AS1 RNA levels in immunoprecipitates were determined by qRT-PCR. Expression levels of SH3PXD2A-AS1 RNA were presented as fold enrichment relative to IgG immunoprecipitates.
Downregulation of SH3PXD2A-AS1 inhibited in vivo tumorigenesis
Sh-SH3PXD2A-AS1-transfected DLD-1 cells or empty-vector-transfected DLD-1 cells Measurement of tumors for up to 24 days after inoculation showed that the sizes of tumors derived from sh-SH3PXD2A-AS1-transfected DLD-1 cells were obviously smaller than those derived from emptyvector-transfected DLD-1 cells (Fig. 5A) . Furthermore, the expression of SH3PXD2A-AS1 1 cells (Fig. 5B) . Additionally, tumor volumes were measured every 4 days in the sh-SH3PXD2A-AS1 and empty vector groups (Fig. 5C ), and tumor weight was markedly lower in the sh-SH3PXD2A-AS1 group than in the empty-vector group (Fig. 5D) . Consistently, immunohistochemical (IHC) analysis showed that tumors formed in the sh-SH3PXD2A-AS1 group exhibited lower ki-67 expression than those in the empty vector group (Fig. 5E) . Thus, these provided insights into the effects of SH3PXD2A-AS1 downregulation on tumorigenesis in vivo. 
SH3PXD2A-AS1 suppressed P57 and KLF2 expression through interaction with EZH2
Recent studies have suggested that lncRNAs are required for epigenetic regulation of target genes through binding with PRC2, thus contributing to cancer progression [30, 35, 36] . EZH2 and SUZ12, as two core components of PRC2 complex, have been shown to be involved in cancer progression [37] [38] [39] . In this study, we examined EZH2 expression in 50 tumor tissue samples, EZH2 was obviously upregulated in CRC tissue samples (Fig. 6A) . Furthermore, EZH2 was markedly overexpressed in SW480 and DLD-1 cells compared with that in HCoEpiC cells (Fig. 6B) . Additionally, EZH2 siRNAs were used to knock down EZH2 expression in SW480 and DLD-1 cells (Fig. 6C) .
The regulatory mechanisms of lncRNAs primarily depend on the distribution of lncRNAs in the cell. Thus, we next determined the distribution of SH3PXD2A-AS1 in SW480 and DLD-1 cells. Our findings showed that SH3PXD2A-AS1 levels were higher in the nucleus than in the cytoplasm (Fig. 6D) , implying that SH3PXD2A-AS1 may regulate the expression of target genes at transcriptional levels. In situ hybridization (ISH) assays using CRC tissue samples and non-tumor samples further demonstrated the distribution and localization of SH3PXD2A-AS1 (Fig. 10B) . To further explore the mechanism of SH3PXD2A-AS1 in CRC progression, Fig. 8 . SH3PXD2A-AS1 exhibited an inverse correlation with expression of P57 and KLF2, which were anti-oncogenes in CRC progression. A. qPCR analysis was used to examine P57 and KLF2 expression levels in DLD-1 cells treated with pcDNA-P57 or pcDNA-KLF2. B. The protein levels of P57 and KLF2 were tested in DLD-1 cells transfected with pcDNA-P57 or pcD-NA-KLF2 using western blot experiments. C. Overexpression of P57 or KLF2 could inhibit cell viability in CRC. D. DLD-1 cells transfected with empty vector, pcDNA-P57, or pcDNA-KLF2 were -tometry. E-F. MTT and colony formation experiments were used to determine the cell viability for pcDNA-SH3PXD2A-AS1 and pcDNA-P57 or pcDNA-KLF2 cotransfected DLD-1 cells. G. The expression levels of P57 and KLF2 were examined in 50 pairs CRC tissues using qRT-PCR, and an inverse correlation was found between SH3PXD2A-AS1 and P57 or KLF2 in CRC. Values are shown as the mean ± s.d in three independent experiments. *P<0.05, **P<0.01. (Fig. 6E) . Endogenous SH3PXD2A-AS1 was obviously enriched in anti-EZH2 RIP fraction. Furthermore, the data showed that endogenous SH3PXD2A-AS1 was also enriched in anti-SUZ12 RIP fraction. These data suggested that SH3PX-D2A-AS1 interacted most strongly with EZH2. Cyclin-dependent protein kinase inhibitors (CKIs), which have indispensable roles in cell cycle control, -velopment and progression of cancer [40] [41] [42] . Because of function of SH3PXD2A-AS1 in modulating the cell cycle in CRC cells, we next examined the alterations of CKIs family members (including P15, P16, P21, P27, P57) in SW480 and DLD-1 cells with SH3PXD2A-AS1 knockdown. Kruppellike factor 2 (KLF2) and phosphatase and tensin homolog deleted from chromosome 10 involved in cell cycle and apoptosis [43] [44] [45] [46] . Thus, we also detected the expression of KLF2 and PTEN in SW480 and DLD-1 cells with SH3PXD2A-AS1 knockdown. The data showed that P57 and KLF2 were remarkably upregulated in SW480 and DLD-1 cells with SH3PXD2A-AS1 knockdown at both mRNA level and protein level, compared with respective controls (Fig. 7A-7B ). Then, qRT-PCR assays showed that both P57 and KLF2 were significantly upregulated in EZH2-depleted SW480 and DLD-1 cells compared with negative controls (Fig. 7C) . Thus, we concluded that P57 and KLF2 may be novel target genes of SH3PXD2A-AS1 in CRC. Chromatin immunoprecipitation (CHIP) assays were performed to further validate our hypothesis that SH3PXD2A-AS1 could mediate suppression of P57 and KLF2 through interaction with EZH2 in CRC. As shown in Fig. 7D , SH3PXD2A-AS1 downregulation decreased the bindings between EZH2 and promoter regions of P57 and KLF2 in SH3PXD2A-AS1-depleted SW480 and DLD-1 cells, relative to respective control cells. Taken together, these results showed that SH3PXD2A-AS1 could recruit EZH2 to promoter regions of P57 and KLF2 to silence P57 and KLF2 expression, thereby mediating CRC cells progression.
Tumor-suppressive function of P57 and KLF2 in CRC P57 is a crucial component of CKIs family, which also includes P15, P16, P21, and P27 [47] . Our previous studies investigated the expression patterns of P57 in CRC tissues, and highlighted P57 as an important anti-oncogene in CRC progression [47, 48] . We also reported that lncRNA HOXA-AS2 mediated CRC proliferation partly through inhibiting P21 and KLF2 expression [30] . In addition, the effects of P15 and P16 on CRC progression have been studied previously [49] [50] [51] .
In this study, we explored the role of P57 in CRC, with a special focus on determining the effects of P57 and KLF2 overexpression on CRC proliferation and cell cycle. P57 and KLF2 were obviously upregulated in DLD-1 cells transfected with pcDNA-P57 or pcDNA- KLF2 at both mRNA and protein levels, compared with respective control group (Fig. 8A-8B ). Moreover, overexpression of P57 or KLF2 could inhibit cell viability in CRC (Fig. 8C) . Additionally, assays showed that overexpression of P57 or KLF2 in DLD-1 cells resulted in G1/G0 phase arrest (Fig. 8D) . Thus, we concluded that P57 and KLF2 exerted tumor-suppressive functions in CRC.
The involvement of P57 and KLF2 in SH3PXD2A-AS1-mediated pro-oncogenic functions in CRC Next, we conducted rescue assays to detect whether P57 and KLF2 were involved in SH3PXD2A-AS1-induced promotion of CRC proliferation. DLD-1 cells were cotransfected with pcDNA-SH3PXD2A-AS1 and pcDNA-P57 or pcDNA-KLF2. Notably, MTT and colonyformation assays revealed that this cotransfection partially reversed the promotion of CRC proliferation mediated by pcDNA-SH3PXD2A-AS1 (Fig. 8E-8F ). Moreover, MTT assays were also used to examine cell vaiblity in DLD-1 cells cotransfected with EZH2 shRNA and pcDNA-P57 or pcDNA-KLF2, thus indirectly revealing the effects of EZH2 on SH3PXD2A-AS1-mediated suppression of P57 and KLF2 (Fig. 11C) . Finally, we further determined that SH3PXD2A-AS1 could negatively modulate the expression of P57 and KLF2 in CRC tissues (Fig. 8G) . These results demonstrated that SH3PXD2A-AS1-mediated oncogenic role is partly through suppressing P57 and KLF2 in CRC.
Discussion
and progression of many malignancies, including CRC [52] [53] [54] . Current progress in RNA sequencing techniques has facilitated the discovery of these critical molecules associated with carcinogenesis [55, 56] . In this study, we analyzed the publicly available data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, and screened SH3PXD2A-AS1 as a novel lncRNA involved in CRC progression. Our results showed that SH3PXD2A-AS1 was markedly upregulated in CRC tissue samples and that SH3PXD2A-AS1 overexpression was associated with tumor size, TNM stage, and lymph node metastasis in patients with CRC. Additionally, SH3PXD2A-AS1 downregulation caused G1/G0 phase arrest, impaired CRC cell proliferation capacity, and promoted apoptosis, whereas overexpression of SH3PXD2A-AS1 had the opposite effects. SH3PXD2A-AS1 in cell proliferation and cell cycle regulation in CRC. The regulatory mechanism of lncRNAs depends primarily on the distribution of lncRNAs in cell. We found that SH3PXD2A-AS1 exhibited higher distribution in nucleus in CRC cell lines, suggesting that SH3PXD2A-AS1 may regulate the expression of target genes at transcriptional levels. Indeed, emerging evidence has demonstrated that lncRNAs can modulate the expression of target genes through binding with PRC2 complex, which affects epigenetic repression of target genes. For example, lncRNA PVT1 could bind with EZH2 to epigenetically silence LATS2 expression, thus contributing to non-small cell lung cancer (NSCLC) proliferation [57] . In our previous study, we also reported that lncRNA SNHG15 could interact with EZH2 in pancreatic cancer [58] . Here, we performed RIP experiments, EZH2 RIP fraction in SW480 and DLD-1 cells. Moreover, SH3PXD2A-AS1 could also interact with SUZ12 in SW480 and DLD-1 cell.
CKIs have been found to affect cell cycle progression and cell apoptosis in multiple cancers [42] . KLF2 and PTEN, critical tumor suppressors, also have indispensable roles in regulating cell cycle and apoptosis [43, 44, 59] . Notably, P57 and KLF2 were markedly upregulated in SH3PXD2A-AS1-depleted CRC cells at both the mRNA and protein levels. Moreover, P57 and KLF2 were also upregulated in EZH2-depleted CRC cell lines, suggesting that P57 and KLF2 may function as novel downstream targets of SH3PXD2A-AS1 in CRC. Thus, we hypothesized that SH3PXD2A-AS1 could epigenetically suppress P57 and KLF2 through interaction with EZH2 in CRC. Furthermore, knockdown of SH3PXD2A-AS1 was found to impair EZH2 binding capacity to the promoter regions of P57 and KLF2 in CRC cells, P57 and KLF2 are SH3PXD2A-AS1/EZH2-mediated target genes. Our previous studies have highlighted P21 and P57 as important anti-oncogenes in CRC progression [47, 48] . P15 and P16 have also been as tumor-suppressive proteins in CRC [49, 51] . In this study, we reported that overexpression of P57 and KLF2 can inhibit proliferative ability of CRC cells, and cause G1/G0 phase arrest. We also found that SH3PXD2A-AS1 negatively regulated the expression of P57 and KLF2 in CRC tissues.
In summary, our findings showed that SH3PXD2A-AS1 was remarkably upregulated in CRC tissues compared with matched non-tumor samples and its overexpression correlated with clinicopathological factors in patients with CRC. This expression pattern of SH3PXD2A-AS1 in CRC helps to fully understand the state of CRC patients. SH3PXD2A-AS1 may be a diagnostic biomarker and prognostic indicator for patients with CRC. In-vitro and in-vivo assays demonstrated that decreased SH3PXD2A-AS1 could inhibit cell proliferation, cause G1/G0 phase arrest, and increased apoptotic rates in CRC. Importantly, mechanistic P57 and KLF2 expression through EZH2-mediated H3K27me3, thus contributing to CRC proliferation. e important insights into CRC pathogenesis, and are expected to facilitate the development of approaches for early diagnosis and targeted therapy of CRC based on lncRNAs. Recent investigations have revealed that antisense transcripts can exert effects via inducing their neighbouring protein-coding genes [60] [61] [62] . However, whether SH3PXD2A-AS1 can modulate SH3PXD2A and other possible target genes is still unclear, and the underlying mechanisms have not yet been explored in this study. Therefore, more efforts should be devoted to elucidate the mechanisms involved in these processes.
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